Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763315 | 0.87 | MMP2 (0.61) | FKBP1AALDH1A1MAPK1CASP3ACHE | |
| SCHEMBL16763314 | 0.87 | MMP2 (0.61) | FKBP1AALDH1A1MAPK1CASP3ACHE | |
| SCHEMBL14895147 | 0.86 | FKBP1A (0.67) | FKBP1AALDH1A1MAPK1ACHELMNA | |
| SCHEMBL9451880 | 0.86 | FKBP1A (0.67) | FKBP1AALDH1A1MAPK1ACHELMNA | |
| SCHEMBL14895148 | 0.86 | FKBP1A (0.67) | FKBP1AALDH1A1MAPK1ACHELMNA | |
| SCHEMBL16164040 | 0.86 | FKBP1A (0.67) | FKBP1AALDH1A1MAPK1ACHELMNA | |
| SCHEMBL15062616 | 0.85 | FKBP1A (1.00) | FKBP1AALDH1A1MAPK1ACHELMNA | |
| SCHEMBL28962073 | 0.84 | MMP2 (0.58) | FKBP1AALDH1A1CASP3ACHEKMT2A | |
| SCHEMBL3099904 | 0.84 | MMP2 (0.58) | FKBP1AALDH1A1CASP3ACHEKMT2A | |
| SCHEMBL15062394 | 0.83 | ALDH1A1 (0.72) | FKBP1AALDH1A1MAPK1ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526732-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-12-31 | — | — | US | disclosed |
| EP-2771334-B1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RES & DEV (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-9090596-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20140309208-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-16 | — | — | US | disclosed |
| WO-2013061005-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309208-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CCL11, CCL2, CCL5 | FKBP1A 1308/4885ALDH1A1 572/4885MAPK1 1624/4885 |
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CCL11, CCL2, CCR1 | FKBP1A 820/4885ALDH1A1 618/4885MAPK1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.